Literature DB >> 7991573

Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration.

F C Richardson1, J A Engelhardt, R R Bowsher.   

Abstract

Accumulation of the antiviral nucleoside analogue fialuridine (FIAU; 1-(2'-deoxy-2'-fluoro-beta-D-arab-inofuranosyl-5-iodouracil) in genomic DNA was examined with a modified version of a recently developed RIA for FIAU. DNA was obtained from tissues of dogs administered FIAU at 0, 1, 2, or 3 mg/kg of body weight per day for 90 days, monkeys administered FIAU at 0 or 25 mg/kg per day for 30 days, and rats administered FIAU at 0, 255, or 510 mg/kg per day for 70 days. FIAU incorporation was observed in all species. In the rat, FIAU was incorporated into DNA of all tissues examined, with highest concentrations in the liver followed by jejunum, spleen, and heart. FIAU was also incorporated into sperm DNA. Incorporation rates were as high as 11,000 pmol of FIAU per mumol of thymidine or 1 FIAU molecule per 90 thymidine molecules. In dogs and rats, the extent of incorporation was dose-dependent. Across species, FIAU concentrations in DNA were not singly dependent on the total dose administered but also may have been dependent on the duration of exposure. These studies show that FIAU accumulates to high concentrations in genomic DNA of liver as well as other tissues during chronic oral administration and suggest that net accumulation of FIAU in DNA may be a critical step in FIAU-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991573      PMCID: PMC45364          DOI: 10.1073/pnas.91.25.12003

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine.

Authors:  L D Lewis; F M Hamzeh; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy.

Authors:  E Arnaudo; M Dalakas; S Shanske; C T Moraes; S DiMauro; E A Schon
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

Review 3.  The relative merits and drawbacks of new nucleoside analogues with clinical potential.

Authors:  B Oberg; N G Johansson
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

4.  Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  O Hantz; H S Allaudeen; T Ooka; E De Clercq; C Trepo
Journal:  Antiviral Res       Date:  1984-08       Impact factor: 5.970

5.  Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.

Authors:  P Huang; S Chubb; W Plunkett
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

6.  Quantitative determination of antiviral nucleoside analog in DNA.

Authors:  M S Chen; M Van Nostrand; S C Oshana
Journal:  Anal Biochem       Date:  1986-08-01       Impact factor: 3.365

7.  Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883.

Authors:  P I Eacho; T L Lanier; C A Brodhecker
Journal:  Carcinogenesis       Date:  1991-09       Impact factor: 4.944

8.  Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases.

Authors:  I Fourel; O Hantz; L Cova; H S Allaudeen; C Trepo
Journal:  Antiviral Res       Date:  1987-11       Impact factor: 5.970

9.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine.

Authors:  C H Chen; Y C Cheng
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

10.  Correlation of cytotoxicity with incorporation of ara-C into DNA.

Authors:  D W Kufe; P P Major; E M Egan; G P Beardsley
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157

View more
  8 in total

1.  Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts.

Authors:  W Lewis; E S Levine; B Griniuviene; K O Tankersley; J M Colacino; J P Sommadossi; K A Watanabe; F W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 2.  Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?

Authors:  G Moyle
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

3.  Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.

Authors:  Maja M Janas; Ivan Zlatev; Ju Liu; Yongfeng Jiang; Scott A Barros; Jessica E Sutherland; Wendell P Davis; Jingxuan Liu; Christopher R Brown; Xiumin Liu; Mark K Schlegel; Lauren Blair; Xuemei Zhang; Biplab Das; Chris Tran; Krishna Aluri; Jing Li; Saket Agarwal; Ramesh Indrakanti; Klaus Charisse; Jayaprakash Nair; Shigeo Matsuda; Kallanthottathil G Rajeev; Tracy Zimmermann; Laura Sepp-Lorenzino; Yuanxin Xu; Akin Akinc; Kevin Fitzgerald; Akshay K Vaishnaw; Peter F Smith; Muthiah Manoharan; Vasant Jadhav; Jing-Tao Wu; Martin A Maier
Journal:  Nucleic Acids Res       Date:  2019-04-23       Impact factor: 16.971

4.  Antiviral L-nucleosides specific for hepatitis B virus infection.

Authors:  M L Bryant; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; P Marion; E Cretton-Scott; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Differential effects of the incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences.

Authors:  K A Staschke; K K Richardson; T E Mabry; A J Baxter; J C Scheuring; D M Huffman; W C Smith; F C Richardson; J M Colacino
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

Review 6.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  TGN1412: From Discovery to Disaster.

Authors:  H Attarwala
Journal:  J Young Pharm       Date:  2010-07

Review 8.  Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans.

Authors:  Franck A Atienzar; Eric A Blomme; Minjun Chen; Philip Hewitt; J Gerry Kenna; Gilles Labbe; Frederic Moulin; Francois Pognan; Adrian B Roth; Laura Suter-Dick; Okechukwu Ukairo; Richard J Weaver; Yvonne Will; Donna M Dambach
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.